Cumberland Pharmaceuticals Reports First Quarter Financial Results

- Diluted earnings per share increased 150% to $0.05

02 May, 2013, 16:05 ET from Cumberland Pharmaceuticals Inc.

NASHVILLE, Tenn., May 2, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2013 financial results.

Net Revenue:  For the three months ended March 31, 2013, net revenue was $10.3 million, in line with net revenues from the first quarter of 2012.

Operating Expenses:  Total operating expenses for the three months ended March 31, 2013, were $8.9 million compared to $9.6 million during the prior year period.  This decrease was driven primarily by the realignment of the sales force in late 2012.

Net Income:  Net income attributable to common shareholders for the three months ended March 31, 2013, was $0.9 million, or $0.05 per diluted share, compared to $0.4 million, or $0.02 per diluted share, for the same period in 2012. 

Cash Flow: Operating cash flows for the three months ended March 31, 2013, were $1.7 million, compared to $2.6 million, for the prior year period. 

Balance Sheet:  As of March 31, 2013, Cumberland had $70.2 million in cash and marketable securities, with approximately $51.2 million in cash and equivalents and $19.0 million in marketable securities.  Total assets at March 31, 2013, were $98.3 million.

"Our progress during the first quarter included top line results from three new Caldolor studies and new international partnerships for India and Indonesia," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We were also pleased with the first quarter financial results maintaining revenues from the prior year quarter, while significantly increasing our net income through the efficient management of our expenses."

Product Highlights

Acetadote®

In January 2013, Cumberland initiated shipments of the Company's Authorized Generic version of Acetadote distributed by Perrigo Company. The Authorized Generic resulted from a License and Supply Agreement with Perrigo and a related Settlement Agreement with Paddock Laboratories, LLC and Perrigo Company signed in November 2012.

On March 19, 2013, the United States Patent and Trademark Office issued U.S. Patent number 8,399,445. The claims of this second Acetadote patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. On April 8, 2013, the new Acetadote patent was listed in the FDA "Orange Book" and it is scheduled to expire in August 2025.

Caldolor®

In February 2013, Cumberland announced the top-line results from two registry studies evaluating the safety and efficacy of Caldolor (ibuprofen) Injection administered over a shortened infusion time in treating pain and fever in adult patients. The studies involved 450 patients receiving Caldolor at 34 leading medical centers throughout the United States.

The first of two registry studies was a phase IV multi-center, open-label surveillance clinical study to assess the safety and efficacy of ibuprofen administered intravenously over five to ten minutes to adult patients in the hospital setting with temperature fever (>101 degrees F) and/or pain (visual analog scale (VAS) assessment >3). Eligible patients were enrolled to receive one of two dose strengths (400 mg for treatment of fever, 800 mg for treatment of pain) of intravenous ibuprofen for up to a 24- hour dosing period. One hundred fifty patients from 13 clinical sites were enrolled in this study. Intravenous ibuprofen reduced fever and pain and the shortened infusion time was well tolerated.

The second of two registry studies was a phase IV multi-center, open-label surveillance clinical study to assess the safety of ibuprofen administered intravenously over five to ten minutes to adult hospitalized patients undergoing surgical procedures. Eligible patients were enrolled to receive 800 mg intravenous ibuprofen administered at induction of anesthesia and could continue Caldolor therapy for up to 24 hours. Three hundred patients from 21clinical sites were enrolled in this study. The shortened infusion time was well tolerated.

In February 2013, Cumberland also announced favorable top line results from a pilot clinical study evaluating the safety and analgesic efficacy of Caldolor (ibuprofen) Injection compared to ketorolac injection in treating pain following knee arthroscopy procedures in adult patients. The study was conducted at the Ohio State University Medical Center. The study enrolled fifty-one patients and the results indicate, compared to patients receiving ketorolac, patients receiving intravenous ibuprofen experienced less postoperative pain prior to discharge. Patients receiving Caldolor also needed fewer narcotics and were less likely to require narcotics prior to discharge. This data supports the benefits of using Caldolor in a pre-emptive model of multimodal analgesia.

International Agreements

In January 2013, Cumberland entered into agreements with India's Sandor Medicaids Pvt. Ltd. and Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the commercialization of Caldolor in those countries. Cumberland also entered into an agreement with GerminMED W.L.L. for the commercialization of Acetadote, Caldolor and Kristalose in the Arabian Peninsula.

Conference Call and Webcast

A conference call and live Internet webcast will be held on Thursday, May 2, 2013 at 4:30 p.m. Eastern Time to discuss the Company's first quarter 2013 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 46598348. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at www.cumberlandpharma.com.

About Acetadote

Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit www.acetadote.com.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit www.caldolor.com.

About Kristalose

Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

March 31, 2013

December 31, 2012

ASSETS

Current assets:

Cash and cash equivalents

$

51,209,544

$

54,349,381

Marketable securities

18,958,810

16,686,136

Accounts receivable, net of allowances

5,967,631

6,017,201

Inventories

5,992,031

6,218,355

Other current assets

3,892,239

3,961,169

Total current assets

86,020,255

87,232,242

Property and equipment, net

1,153,426

1,188,914

Intangible assets, net

10,403,974

9,476,798

Other assets

700,095

695,777

Total assets

$

98,277,750

$

98,593,731

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable

$

3,427,256

$

2,790,554

Other current liabilities

4,808,531

5,264,806

Total current liabilities

8,235,787

8,055,360

Revolving line of credit

4,359,951

4,359,951

Other long-term liabilities

652,371

611,933

Total liabilities

13,248,109

13,027,244

Commitments and contingencies

Equity:

Shareholders' equity:

Common stock—no par value; 100,000,000

shares authorized; 18,549,749 and 18,937,107

shares issued and outstanding as of March 31,

2013 and December 31, 2012, respectively

65,818,995

67,197,167

Retained earnings

19,353,863

18,499,154

Total shareholders' equity

85,172,858

85,696,321

Noncontrolling interests

(143,217)

(129,834)

Total equity

85,029,641

85,566,487

Total liabilities and equity

$

98,277,750

$

98,593,731

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)

Three months ended March 31,

2013

2012

Net revenues

$

10,258,132

$

10,256,212

Costs and expenses:

Cost of products sold

1,108,635

848,550

Selling and marketing

3,673,939

4,980,553

Research and development

1,448,718

1,404,022

General and administrative

2,575,739

2,265,025

Amortization

125,050

112,047

Total costs and expenses

8,932,081

9,610,197

Operating income

1,326,051

646,015

Interest income

92,377

72,281

Interest expense

(17,735)

(22,427)

Income before income taxes

1,400,693

695,869

Income tax expense

(559,367)

(282,028)

Net income

841,326

413,841

Net loss at subsidiary attributable to noncontrolling interests

13,383

9,367

Net income attributable to common shareholders

$

854,709

$

423,208

Earnings per share attributable to common shareholders

- basic

$

0.05

$

0.02

- diluted

$

0.05

$

0.02

Weighted-average shares outstanding

- basic

18,758,383

20,007,998

- diluted

18,925,165

20,234,438

Comprehensive income

$

841,326

$

413,841

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Three months ended March 31,

2013

2012

Cash flows from operating activities:

Net income

$

841,326

$

413,841

Adjustments to reconcile net income to net cash provided by operating

activities:

Depreciation and amortization expense

290,508

217,263

Deferred tax expense

65,413

Share-based compensation

128,625

214,381

Excess tax benefit derived from exercise of stock options

(478,698)

(191,081)

Noncash interest expense

6,019

6,019

Noncash investment gains (losses)

10,571

(8,800)

Net changes in assets and liabilities affecting operating activities:

Accounts receivable

49,570

2,619,523

Inventory

226,324

(230,784)

Other current assets and other assets

(8,298)

(324,954)

Accounts payable and other current liabilities

492,983

(282,862)

Other long-term liabilities

46,308

178,120

Net cash provided by operating activities

1,670,651

2,610,666

Cash flows from investing activities:

Additions to property and equipment

(60,911)

(32,800)

Purchases of marketable securities

(2,970,000)

(15,992,822)

Proceeds from sale of marketable securities

686,755

Additions to intangible assets

(961,013)

(180,787)

Net cash used in investment activities

(3,305,169)

(16,206,409)

Cash flows from financing activities:

Net borrowings on line of credit

250,000

Proceeds from exercise of stock options

(41,292)

545,601

Excess tax benefit derived from exercise of stock options

478,698

191,081

Repurchase of common shares

(1,942,725)

(2,346,524)

Net cash used in financing activities

(1,505,319)

(1,359,842)

Net decrease in cash and cash equivalents

(3,139,837)

(14,955,585)

Cash and cash equivalents at beginning of period

54,349,381

70,599,146

Cash and cash equivalents at end of period

$

51,209,544

$

55,643,561

Supplemental disclosure of cash flow information:

Non-cash investing and financing activities:

Net change in unpaid additions to intangibles, property and equipment

$

160,272

$

82,696

 

 

SOURCE Cumberland Pharmaceuticals Inc.



RELATED LINKS

http://www.cumberlandpharma.com